文献速递白血病

STAT3-MYC轴通过调控SLC1A5和氧化磷酸化促进白血病干细胞存活

The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation.
PubMed 文献 · Blood · 2022-01-01

该研究利用原代人AML标本的遗传学和药理学策略,发现STAT3通过调控MYC转录进而控制SLC1A5表达,维持LSCs的氧化磷酸化。抑制STAT3可选择性杀伤初诊和复发AML患者的干/祖细胞,同时保留正常造血细胞。

要点

  • STAT3调控AML特异性MYC表达,MYC转录激活SLC1A5。
  • SLC1A5抑制降低谷氨酰胺、谷胱甘肽和TCA循环代谢物,抑制OXPHOS。
  • 新型STAT3小分子抑制剂选择性诱导AML干细胞/祖细胞死亡。

核心结论

  • STAT3-MYC-SLC1A5轴是连接STAT3与能量代谢的关键调控机制,促进AML干细胞存活。
  • 抑制STAT3可选择性杀伤初诊和复发AML患者的干细胞和祖细胞,同时保留正常造血细胞。

研究设计与样本

  • 使用原代人AML标本,采用遗传学和药理学策略进行研究。
  • 使用一种新型小分子STAT3抑制剂(结合STAT3并破坏STAT3-DNA相互作用)评估STAT3的生物学作用。

主要发现

  • STAT3介导LSCs中的OXPHOS。
  • STAT3调控AML特异性MYC表达,MYC控制中性氨基酸转运体基因SLC1A5的转录。
  • 遗传抑制MYC或SLC1A5可重现STAT3抑制所致的OXPHOS损伤。
  • 抑制SLC1A5降低细胞内谷氨酰胺、谷胱甘肽和多种TCA循环代谢物水平,导致TCA循环活性降低和OXPHOS抑制。
  • STAT3抑制选择性导致初诊和复发AML患者的AML干细胞和祖细胞死亡,同时保留正常造血细胞。

临床怎么用

  • STAT3-MYC-SLC1A5轴可作为靶向AML干细胞的潜在治疗策略。
  • 新型STAT3小分子抑制剂在体外选择性清除AML干/祖细胞,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is characterized by the presence of leukemia stem cells (LSCs), and failure to fully eradicate this population contributes to disease persistence/relapse. Prior studies have characterized metabolic vulnerabilities of LSCs, which demonstrate preferential reliance on oxidative phosphorylation (OXPHOS) for energy metabolism and survival. In the present study, using both genetic and pharmacologic strategies in primary human AML specimens, we show that signal transducer and activator of transcription 3 (STAT3) mediates OXPHOS in LSCs. STAT3 regulates AML-specific expression of MYC, which in turn controls transcription of the neutral amino acid transporter gene SLC1A5. We show that genetic inhibition of MYC or SLC1A5 acts to phenocopy the impairment of OXPHOS observed with STAT3 inhibition, thereby establishing this axis as a regulatory mechanism linking STAT3 to energy metabolism. Inhibition of SLC1A5 reduces intracellular levels of glutamine, glutathione, and multiple tricarboxylic acid (TCA) cycle metabolites, leading to reduced TCA cycle activity and inhibition of OXPHOS. Based on these findings, we used a novel small molecule STAT3 inhibitor, which binds STAT3 and disrupts STAT3-DNA, to evaluate the biological role of STAT3. We show that STAT3 inhibition selectively leads to cell death in AML stem and progenitor cells derived from newly diagnosed patients and patients who have experienced relapse while sparing normal hematopoietic cells. Together, these findings establish a STAT3-mediated mechanism that controls energy metabolism and survival in primitive AML cells.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Amaya ML, Inguva A, Pei S, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022. PMID: 34525179. doi:10.1182/blood.2021013201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。